title: Re: Wells et al.: Aflibercept, Bevacizumab, or Ranibizumab for diabetic macular edema: Two-year results from a comparative effectiveness randomized clinical trial (Ophthalmology 2016;123:1351-1358).
authors.affiliation: Retina Consultants, Poway, California. Electronic address: tornambepe@aol.com.
authors.forename: Paul
authors.initials: P
authors.lastname: Tornambe
mesh_terms: D020533:Angiogenesis Inhibitors; D000068258:Bevacizumab; D006801:Humans; D058449:Intravitreal Injections; D008269:Macular Edema; D000069579:Ranibizumab; D040262:Receptors, Vascular Endothelial Growth Factor; D011993:Recombinant Fusion Proteins; D042461:Vascular Endothelial Growth Factor A
chemical_list: D020533:Angiogenesis Inhibitors; D011993:Recombinant Fusion Proteins; D042461:Vascular Endothelial Growth Factor A; C533178:aflibercept; D000068258:Bevacizumab; D040262:Receptors, Vascular Endothelial Growth Factor; D000069579:Ranibizumab